Ann: SleepCheck Now Available in 36 Countries, page-194

RAP is a gift at this share price, topped up 30% recently and plan to continue.

This is just the standard line fro me, but I see no reason it is not true... RAP has a small growing footprint in Australia as remote airway tool to aid/standardise/triage respiratory disease. Setting a stage for first world integration, proof of concept in a friendly area. The market is huge and developing rapidly towards mobile device tech., RAP is one of the few with science to support efficacy, continued development paths with potential to triage and track COVID related use in the medium term (next 6 months).

Europe or Asia are the big steps in the medium term, followed by US hopefully with the pressure on the FDA to re-evaluate their choice based on real world arguments, not arguments based on conjecture and lack of numbers, and probably slightly biased by the US stance on home grown tech being preferred. We should have a company registered in the US.